20.01
price down icon15.50%   -3.67
pre-market  Pre-mercato:  20.22   0.21   +1.05%
loading

Perché le azioni Newamsterdam Pharma Company Nv (NAMS) sono in ribasso?

Abbiamo notato un calo di 15.50% nelle azioni di Newamsterdam Pharma Company Nv (NAMS) durante la sessione di negoziazione di 2024-11-20. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!
2023-10-23:

Shares of Newamsterdam Pharma Company (NAMS) dropped by 10.07% from $7.05 to $6.34 in the trading on Monday, October 23, 2023. The reason why NAMS stock down is due to a change in the management board. On Monday, Newamsterdam Pharma announced the appointment of Ian Somaiya as its Chief Financial Officer. Mr. Somaiya boasts over twenty-five years of experience in senior leadership roles within the biopharmaceutical industry. Notably, during his 20-year tenure on Wall Street, he gained recognition as a highly regarded industry equity analyst, conducting extensive research on over 100 biotechnology companies across various therapeutic areas, technology platforms, and development stages. His research earned him the distinction of Best on the Street by The Wall Street Journal for multiple consecutive years. Ian Somaiya holds a B.A. in Biology and Neuroscience from New York University. However, despite his impressive credentials, investors reacted cautiously to this news, leading to a decline in the stock's price.

$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Capitalizzazione:     |  Volume (24 ore):